| Ytd | 40.20% | |
| 1y | 87.36% |
| Open | 175.83 | Prev Close | 175.83 | Low | 175.60 | High | 184.90 | Mkt Cap | 27.82B |
| Vol | 2.10M | Avg Vol | 1.77M | EPS | 5.50 | P/E | 33.43 | Forward P/E | 31.00 |
| Beta | 1.49 | Short Ratio | 4.89 | Inst. Own | 106.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 151.81 | 200-d Avg | 129.79 | 1yr Est | 153.26 |
ILMN News
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably alrea
Piper Sandler analyst David Westenberg maintains Illumina (NASDAQ:ILMN) with a Overweight and rai
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t
Guggenheim analyst Subbu Nambi maintains Illumina (NASDAQ:ILMN) with a Buy and raises the price t
Swiss pharma and diagnostics giant Roche on Monday launched its long-awaited Axelios gene sequencer
Bernstein analyst Eve Burstein reinstates Illumina (NASDAQ:ILMN) with a Market Perform and announ
Barclays analyst Luke Sergott maintains Illumina (NASDAQ:ILMN) with a Underweight and raises the
JP Morgan analyst Casey Woodring upgrades Illumina (NASDAQ:ILMN) from Neutral to Overweight and r
StrataMap Spatial meets the growing demand for scalable spatial biology studies from research and bi
Integrated, push-button oncology research workflows give customers a simplified path from library pr
Guggenheim analyst Subbu Nambi maintains Illumina (NASDAQ:ILMN) with a Buy and raises the price t